ZA200106585B - Triazole compounds with dopamine-D3-receptor affinity. - Google Patents

Triazole compounds with dopamine-D3-receptor affinity. Download PDF

Info

Publication number
ZA200106585B
ZA200106585B ZA200106585A ZA200106585A ZA200106585B ZA 200106585 B ZA200106585 B ZA 200106585B ZA 200106585 A ZA200106585 A ZA 200106585A ZA 200106585 A ZA200106585 A ZA 200106585A ZA 200106585 B ZA200106585 B ZA 200106585B
Authority
ZA
South Africa
Prior art keywords
alkyl
phenyl
formula
compound
halogen
Prior art date
Application number
ZA200106585A
Other languages
English (en)
Inventor
Dorothea Starck
Hans-Joerg Treiber
Liliane Unger
Barbara Neumann-Schultz
Kai Blumbach
Dietmar Schoebel
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of ZA200106585B publication Critical patent/ZA200106585B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
ZA200106585A 1999-01-12 2001-08-10 Triazole compounds with dopamine-D3-receptor affinity. ZA200106585B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19900811 1999-01-12

Publications (1)

Publication Number Publication Date
ZA200106585B true ZA200106585B (en) 2002-08-12

Family

ID=7894006

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA200106584A ZA200106584B (en) 1999-01-12 2001-08-10 Triazole compounds with dopamine-D3-receptor affinity.
ZA200106585A ZA200106585B (en) 1999-01-12 2001-08-10 Triazole compounds with dopamine-D3-receptor affinity.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ZA200106584A ZA200106584B (en) 1999-01-12 2001-08-10 Triazole compounds with dopamine-D3-receptor affinity.

Country Status (28)

Country Link
US (3) US6602867B1 (pt)
EP (3) EP1144405B1 (pt)
JP (3) JP2002534521A (pt)
KR (3) KR100775720B1 (pt)
CN (3) CN1347414A (pt)
AR (3) AR022230A1 (pt)
AT (3) ATE449768T1 (pt)
AU (3) AU772948B2 (pt)
BG (2) BG65105B1 (pt)
BR (2) BR0007504A (pt)
CA (3) CA2359942A1 (pt)
CO (3) CO5150182A1 (pt)
CZ (2) CZ303926B6 (pt)
DE (3) DE50015576D1 (pt)
ES (2) ES2288839T3 (pt)
HK (1) HK1045311B (pt)
HR (1) HRP20010590A2 (pt)
HU (2) HUP0200709A3 (pt)
ID (2) ID29552A (pt)
IL (3) IL144136A0 (pt)
NO (2) NO20013444D0 (pt)
NZ (2) NZ512864A (pt)
PL (2) PL201889B1 (pt)
SK (2) SK9862001A3 (pt)
TR (2) TR200102025T2 (pt)
TW (1) TWI274750B (pt)
WO (3) WO2000042036A1 (pt)
ZA (2) ZA200106584B (pt)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9810876D0 (en) 1998-05-20 1998-07-22 Smithkline Beecham Plc Compounds
ES2255311T3 (es) 1998-10-08 2006-06-16 Smithkline Beecham Plc Derivados de tetrahidrobenzazepina utiles como moduladores de los receptores d3 de dopamina (agentes anti-psicoticos).
AR022230A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion
US7229986B2 (en) * 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
AR035369A1 (es) 2000-11-14 2004-05-12 Smithkline Beecham Plc Derivados de tetrahidrobenzazepina composiciones farmaceuticas que los comprenden, el uso de dichos derivados en la fabricacion de medicamentos, e intermediarios utiles en la preparacion de dichos compuestos
HU227543B1 (en) * 2001-09-28 2011-08-29 Richter Gedeon Nyrt N-[4-(2-piperazin- and 2-piperidin-1-yl-ethyl)-cyclohexyl]-sulfon- and sulfamides, process for their preparation, their use and pharmaceutical compositions containing them
GB0130219D0 (en) * 2001-12-18 2002-02-06 Pfizer Ltd Compounds for the treatment of sexual dysfunction
WO2003062205A1 (en) * 2001-12-21 2003-07-31 Smithkline Beecham P.L.C. 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
US7314937B2 (en) * 2002-03-21 2008-01-01 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine H3 receptor antagonists, preparation and therapeutic uses
MY133587A (en) 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use
DE10304870A1 (de) 2003-02-06 2004-08-19 Abbott Gmbh & Co. Kg Triazolverbindungen und ihre therapeutische Verwendung
ATE397755T1 (de) * 2003-03-17 2008-06-15 Bayer Healthcare Ag Diagnostik- und therapie- verfahren von mit dopaminrezeptor d3 (drd3) verbundenen krankheiten
US6919342B2 (en) 2003-06-05 2005-07-19 Abbott Gmbh & Co. Kg Triazole compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
US20080207685A1 (en) * 2003-11-20 2008-08-28 Eli Lilly And Company Heterocyclic Compounds As Modulators Of Peroxisome Proliferator Activated Receptors, Useful For The Treatment And/Or Prevention Of Disorders Modulated By A Ppar
KR20050054084A (ko) * 2003-12-03 2005-06-10 한국전자통신연구원 수신 환경에 기반한 위성 상태 데이터 분배 기능을 가지는위성관제 시스템 및 그 방법
US7855298B2 (en) * 2004-02-23 2010-12-21 Glaxo Group Limited Azabicyclo (3.1.0.) hexane derivatives useful as modulators of dopamine D3 receptors
EP1737851A1 (en) * 2004-03-08 2007-01-03 Glaxo Group Limited Tetrahydrobenzazepine derivatives as modulators of dopamine d3 receptors (antipsychotic agents)
WO2005090320A2 (en) * 2004-03-12 2005-09-29 Wyeth Triazole derivatives and method of using the same to treat hiv infections
GB0412314D0 (en) 2004-06-02 2004-07-07 Glaxo Group Ltd Compounds
DE102004027358A1 (de) 2004-06-04 2005-12-29 Abbott Gmbh & Co. Kg Pyrimidinverbindungen und ihre Verwendung
GB0413879D0 (en) * 2004-06-21 2004-07-21 Glaxo Group Ltd Compounds
GB0414795D0 (en) * 2004-07-01 2004-08-04 Glaxo Group Ltd Compounds
ES2340941T3 (es) 2004-08-09 2010-06-11 ABBOTT GMBH & CO. KG Compuestos de 4-piperazinil-pirimidina adecuados para tretar trastornos que responden a modulacion del receptor d 3 de dopamina.
WO2006020959A2 (en) * 2004-08-13 2006-02-23 Amgen Inc. Substituted benzofused heterocycles
BRPI0518823A2 (pt) 2004-12-02 2008-12-09 Abbott Gmbh & Co Kg compostos de triazol adequados para o tratamento de transtornos que respondam À modulaÇço do receptor d3 da dopamina
GB0507602D0 (en) 2005-04-14 2005-05-18 Glaxo Group Ltd Compounds
GB0507680D0 (en) 2005-04-15 2005-05-25 Glaxo Group Ltd Compounds
WO2006133945A1 (en) * 2005-06-14 2006-12-21 Glaxo Group Limited Novel compounds
AU2006338265B2 (en) 2005-08-18 2011-04-14 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
ATE487715T1 (de) * 2005-08-22 2010-11-15 Glaxo Group Ltd Triazolderivate als modulatoren von dopamin-d3- rezeptoren
WO2007028145A2 (en) * 2005-09-02 2007-03-08 Dara Biosciences, Inc. Agents and methods for reducing protein tyrosine phosphatase 1b activity in the central nervous system
WO2007120528A2 (en) * 2006-03-31 2007-10-25 La Jolla Pharmaceutical Company Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases
CA2677481C (en) 2007-02-08 2015-07-07 Synta Pharmaceuticals Corp. Triazole compounds that modulate hsp90 activity
TW201011003A (en) * 2008-08-08 2010-03-16 Synta Pharmaceuticals Corp Triazole compounds that modulate HSP90 activity
US9227944B2 (en) 2008-10-10 2016-01-05 Institute Of Pharmacology And Toxicology Academy Of Military Science P.L.A. China Dopamine D3 receptor ligands and preparation and medical uses of the same
WO2010040274A1 (zh) 2008-10-10 2010-04-15 中国人民解放军军事医学科学院毒物药物研究所 新型多巴胺d3受体配体，其制备方法及其医药用途
US9326955B2 (en) * 2008-10-31 2016-05-03 Loyola University Chicago Combination pharmaceuticals and methods thereof using proteinacious channels as treatments for medical conditions
ES2523766T3 (es) * 2009-12-22 2014-12-01 Cephalon, Inc Hexahidrocromeno[3,4-b]pirroles sustituidos con afinidad por la familia de los receptores de serotonina (5-HT)
EP2687507B1 (en) * 2011-03-14 2016-03-09 Taisho Pharmaceutical Co., Ltd. Nitrogen-containing condensed heterocyclic compound
EA201492069A1 (ru) * 2012-05-30 2015-03-31 Ф.Хоффманн-Ля Рош Аг Соединения триазола в качестве ингибиторов фосфодиэстеразы 10 (pde10)
RU2561063C1 (ru) * 2014-07-01 2015-08-20 Общество с ограниченной ответственностью "Научно-производственное объединение "Фарматрон" (НПО "Фарматрон") Способ коррекции неврологических нарушений при хронической алкогольной интоксикации
GB201415573D0 (en) 2014-09-03 2014-10-15 Cancer Therapeutics Crc Pty Ltd Compounds
US10005792B2 (en) 2014-09-03 2018-06-26 Ctxt Pty. Ltd. Aminoindane-, aminotetrahydronaphthalene- and aminobenzocyclobutane-derived PRMT5-inhibitors
US10494376B2 (en) 2014-09-03 2019-12-03 Ctxt Pty. Ltd. Tetrahydroisoquinoline derived PRMT5-inhibitors
GB201604022D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604029D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604030D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604031D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604027D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
GB201604020D0 (en) 2016-03-09 2016-04-20 Ctxt Pty Ltd Compounds
JP7343170B2 (ja) * 2017-05-12 2023-09-12 ボード オブ トラスティーズ オブ ザ サザン イリノイ ユニバーシティ オン ビハーフ オブ サザン イリノイ ユニバーシティ エドワーズビル ３，４，５－三置換－１，２，４－トリアゾールおよび３，４，５－三置換－３－チオ－１，２，４－トリアゾール、ならびにそれらの使用
US10941153B2 (en) * 2018-05-31 2021-03-09 Regents Of The University Of Minnesota Substituted phenethylamine derivatives
GB202117129D0 (en) * 2021-11-26 2022-01-12 Epidarex Exeed Ltd Compounds

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4408049A (en) 1980-09-17 1983-10-04 The Upjohn Company Substituted piperazinyl-1,2,4-triazoles
US4338453A (en) 1980-09-17 1982-07-06 The Upjohn Company Aminoalkyl-1,2,4-triazoles
US4577020A (en) * 1983-01-25 1986-03-18 The Upjohn Company Aminoalkyl and aminoalkenyl triazoles as anti-psychotic agents
FR2601952B1 (fr) 1986-07-23 1988-11-25 Carpibem Nouveaux derives amino alkyl thio de triazolopyridine ou triazoloquinoline, leurs procedes de preparation, medicaments les contenant, utiles notamment comme antalgiques
AU644500B2 (en) * 1990-12-20 1993-12-09 Merrell Dow Pharmaceuticals Inc. 3-aryl-5-alkylthio-4h-1,2,4-triazoles for treatment of hyperreflexia due to spinal trauma
EP0586525B1 (en) 1991-05-20 1997-04-16 PHARMACIA & UPJOHN COMPANY Carboxamido-(1,2n)-carbocyclic-2-aminotetralin derivatives
RO117847B1 (ro) 1991-11-05 2002-08-30 Smithkline Beecham Corp Derivati de indan, procedeu de preparare, compozitie farmaceutica care ii contine si metoda de tratament
FR2687146B1 (fr) 1992-02-12 1994-04-01 Adir Cie Nouveaux derives de pyrrolidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CN1129428C (zh) 1993-04-27 2003-12-03 史密丝克莱恩比彻姆公司 内皮素受体拮抗剂
DE4338396A1 (de) * 1993-11-10 1995-05-11 Basf Ag N-Substituierte Azabicycloalkan-Derivate, ihre Herstellung und Verwendung
FR2722194B1 (fr) 1994-07-06 1996-08-23 Adir Nouveaux derives de benzopyrane, leur procede de preparation et les compositions pharmacuetiques qui les contiennent
DE4425144A1 (de) 1994-07-15 1996-01-18 Basf Ag Triazolverbindungen und deren Verwendung
EP0793653A1 (en) * 1994-11-23 1997-09-10 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
JPH11503116A (ja) 1995-03-27 1999-03-23 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 二環式アミン誘導体および抗精神病薬としてのそれらの使用
AU5272296A (en) * 1995-04-06 1996-10-23 Novo Nordisk A/S Benzopyranopyrrole compounds, their preparation and use
GB9518572D0 (en) 1995-09-12 1995-11-15 Smithkline Beecham Plc Compounds
EP0861234A1 (en) * 1995-11-10 1998-09-02 Novo Nordisk A/S Enantiomers of cis-benz e]indole compounds, their preparation and utility as dopamine-d3 receptor selective agents
FR2742149B1 (fr) * 1995-12-11 1998-02-13 Inst Nat Sante Rech Med Nouveaux derives de 2-naphtamides et leurs applications therapeutiques
DE19600934A1 (de) * 1996-01-12 1997-07-17 Basf Ag Substituierte Aza- und Diazacycloheptan- und Cyclooctanverbindungen und deren Verwendung
US5688950A (en) 1996-04-23 1997-11-18 Neurogen Corporation Tricyclic aminoalkylcarboxamides; novel dopamine D3 receptor subtype specific ligands
ATE232850T1 (de) 1996-05-11 2003-03-15 Smithkline Beecham Plc Tetrahydroisoquinoline derivate als modulatoren von dopamine d3 rezeptoren
DE69724259T2 (de) * 1996-05-31 2004-06-09 Pharmacia & Upjohn Co., Kalamazoo Arylsubstituierte cyclische amine als selektive dopamin-d3-liganden
GB9612153D0 (en) 1996-06-11 1996-08-14 Smithkline Beecham Plc Compounds
CA2263284A1 (en) 1996-08-14 1998-02-19 Smithkline Beecham P.L.C. Tetrahydroisoquinoline derivatives and their pharmaceutical use
JPH10195056A (ja) * 1996-11-12 1998-07-28 Takeda Chem Ind Ltd 縮合ベンゼン誘導体、その製造法および剤
NZ335711A (en) 1996-12-06 2000-10-27 Abbott Lab Substituted benzopyranopyrrole and benzopyranopyridine derivatives
FR2760014B1 (fr) 1997-02-27 1999-04-09 Adir Nouveaux composes de 2-amino indane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
GB9708694D0 (en) * 1997-04-30 1997-06-18 Smithkline Beecham Plc Compounds
GB9708805D0 (en) 1997-05-01 1997-06-25 Smithkline Beecham Plc Compounds
EP0983244A1 (en) * 1997-05-03 2000-03-08 Smithkline Beecham Plc Tetrahydroisoquinoline derivatives as modulators of dopamine d3 receptors
GB9709303D0 (en) 1997-05-09 1997-06-25 Smithkline Beecham Plc Compounds
GB9710366D0 (en) * 1997-05-20 1997-07-16 Biocompatibles Ltd Stent deployment device
FR2764890B1 (fr) * 1997-06-24 1999-08-27 Adir Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
DE19728996A1 (de) * 1997-07-07 1999-01-14 Basf Ag Triazolverbindungen und deren Verwendung
AR022230A1 (es) 1999-01-12 2002-09-04 Abbott Gmbh & Co Kg Compuestos de triazol, composicion farmaceutica que los comprende y uso de los mismos para preparar dicha composicion

Also Published As

Publication number Publication date
CA2359948C (en) 2010-09-21
BG65105B1 (bg) 2007-02-28
JP2002534519A (ja) 2002-10-15
TR200102025T2 (tr) 2002-05-21
EP1140907B1 (de) 2007-07-11
NZ512864A (en) 2003-04-29
US6579892B1 (en) 2003-06-17
CA2359948A1 (en) 2000-07-20
TR200102026T2 (tr) 2001-12-21
CO5150224A1 (es) 2002-04-29
CA2359942A1 (en) 2000-07-20
AR022230A1 (es) 2002-09-04
US6583166B1 (en) 2003-06-24
HUP0200709A3 (en) 2004-07-28
DE50014472D1 (de) 2007-08-23
HRP20010590A2 (en) 2003-08-31
KR100730667B1 (ko) 2007-06-21
CZ303926B6 (cs) 2013-06-26
AR022229A1 (es) 2002-09-04
ID29552A (id) 2001-09-06
CN1345319A (zh) 2002-04-17
KR100687682B1 (ko) 2007-02-28
TWI274750B (en) 2007-03-01
SK9852001A3 (en) 2002-04-04
CA2359952A1 (en) 2000-07-20
AU772948B2 (en) 2004-05-13
EP1140908B1 (de) 2009-03-04
BG105783A (en) 2002-03-29
PL350246A1 (en) 2002-12-02
EP1140907A1 (de) 2001-10-10
IL144137A0 (en) 2002-05-23
PL200238B1 (pl) 2008-12-31
US6602867B1 (en) 2003-08-05
BR0007500A (pt) 2001-10-23
WO2000042037A1 (de) 2000-07-20
ATE424398T1 (de) 2009-03-15
DE50015576D1 (de) 2009-04-16
CO5150227A1 (es) 2002-04-29
HUP0200709A2 (hu) 2002-07-29
AU2541200A (en) 2000-08-01
NO20013444L (no) 2001-07-11
CO5150182A1 (es) 2002-04-29
AR022228A1 (es) 2002-09-04
IL144136A0 (en) 2002-05-23
KR100775720B1 (ko) 2007-11-09
AU2289700A (en) 2000-08-01
NO20013443D0 (no) 2001-07-11
SK9862001A3 (en) 2002-04-04
CN1345318A (zh) 2002-04-17
PL201889B1 (pl) 2009-05-29
JP4933694B2 (ja) 2012-05-16
PL349841A1 (en) 2002-09-23
JP2002534520A (ja) 2002-10-15
AU2436700A (en) 2000-08-01
BR0007504A (pt) 2001-10-02
ID29930A (id) 2001-10-25
NO20013444D0 (no) 2001-07-11
ATE449768T1 (de) 2009-12-15
ES2288839T3 (es) 2008-02-01
ES2334326T3 (es) 2010-03-09
ATE366729T1 (de) 2007-08-15
CZ20012550A3 (cs) 2002-02-13
KR20070032830A (ko) 2007-03-22
NO20013443L (no) 2001-07-12
CN1149209C (zh) 2004-05-12
EP1144405B1 (de) 2009-11-25
HUP0200522A3 (en) 2003-05-28
JP4615125B2 (ja) 2011-01-19
BG65086B1 (bg) 2007-02-28
DE50015802D1 (de) 2010-01-07
ZA200106584B (en) 2002-08-12
JP2002534521A (ja) 2002-10-15
CN1347414A (zh) 2002-05-01
HK1045311A1 (en) 2002-11-22
CN1267430C (zh) 2006-08-02
HK1045311B (zh) 2007-03-30
KR20010086471A (ko) 2001-09-12
EP1140908A1 (de) 2001-10-10
NZ512830A (en) 2003-08-29
CZ20012551A3 (cs) 2002-03-13
HUP0200522A2 (en) 2002-06-29
EP1144405A1 (de) 2001-10-17
BG105784A (en) 2002-02-28
WO2000042038A1 (de) 2000-07-20
IL144136A (en) 2006-12-10
AU773047B2 (en) 2004-05-13
KR20010086470A (ko) 2001-09-12
WO2000042036A1 (de) 2000-07-20

Similar Documents

Publication Publication Date Title
ZA200106585B (en) Triazole compounds with dopamine-D3-receptor affinity.
RU2299199C2 (ru) Новые производные 4,5-дигидро-1h-пиразола, имеющие cb1-антагонистическую активность
AU2005217602B2 (en) 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines as 5-HT2C receptor agonists
JP5701758B2 (ja) Ｈｄｍ２配位子としてのピロリジン−２−オン
US8912220B2 (en) Compounds and methods of use thereof
US20070265330A1 (en) Substituted gamma lactams as therapeutic agents
PL220722B1 (pl) Benzoazepinowe pochodne, zawierająca je kompozycja farmaceutyczna i ich zastosowania do wytwarzania leku i do leczenia chorób neurologicznych
EP1713778A1 (en) Benzazepine derivatives as histamine h3 antagonists
US20030229096A1 (en) Substituted imidazol-pyridazine derivatives
AU2005313550A1 (en) Indenyl derivatives and use thereof for the treatment of neurological disorders
TW201623260A (zh) 新穎二取代１，２，４－三化合物
CA2927518C (en) Sulfur-containing bicyclic compound
AU2008262360B2 (en) Urotensin II receptor antagonists
EP2252599A1 (en) Triazole amide derivatives for use in therapy
US7465744B2 (en) Triazole compounds and the therapeutic use thereof
JP2007513197A (ja) 統合失調症の治療のための複素環式置換インダン誘導体および関連化合物
JP2007513197A6 (ja) 統合失調症の治療のための複素環式置換インダン誘導体および関連化合物
JP3786985B2 (ja) ピロリジノン誘導体
MXPA01006816A (en) Triazole compounds with dopamine-d3-receptor affinity
MXPA00002601A (en) 3-substituted tetrahydropyridopyrimidinone derivatives, method for producing the same, and their use